Long-Acting/Extended Release (LA/ER) Antiretroviral Research Resource Program (LEAP) Investigator Meeting & Annual Workshop - 2020


Saturday, March 7, 2020
Boston Marriott Copley Place


Charles Flexner, Johns Hopkins University
Where are we LEAPing Next?! and Overview of Workshop

PLENARY SESSION 1: Current Status of Existing Technologies:
10-Minute Presentations followed by Q & A (Charles Flexner, Moderator):

Peter Williams, Janssen
Current status of the Janssen LA/ER pipeline

William Spreen, ViiV Healthcare
Current status of the ViiV LA/ER pipeliner
Jay Grobler, Merck
Current status of the Merck LA/ER pipeline
Martin Rhee, Gilead Sciences
Current status of the Gilead LA/ER pipeline
Janssen, ViiV, Merck, Gilead
Industry Panel Discussion, Q&A

Mark Mirochnick, Boston University
Status of Infant and Pediatric Development Programs for LA ARV Formulations

Marco Siccardi, University of Liverpool
Update from the LEAP Modeling and Simulation Core

Plenary Session 2: Novel approaches to LA/ER Drug Delivery:
10-Minute Presentations followed by Five-Minute Q & A (Andrew Owen, Moderator)

Leah Johnson, RTI
Bioerodable Tenofovir Implants for HIV Prevention

Eric Appel, Stanford University
Injectable Hydrogels for the Ultra-Long Term Stabilization and Delivery of Anti-HIV Drugs

S. Rahima Benhabbour, UNC Chapel Hill
Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery

Ryan Donnelly, Queens University
Transcutaneous Microneedles for Antiretroviral Drug Delivery

Cherise Scott, Unitaid
Unitaid Programs to Support the Development of LA formulations for HIV, Tuberculosis, and Malaria
Participant Discussion
The Future Role of LEAP in Long-acting Drug and Formulation Development